Thirteen states reported high or very high levels of flu-like illness last week, about double from the week before.

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

We lived in India when I was a child, and I also grew up with the idea that there were parts of the world where vaccines were ...

As we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...

This year marks the 50-year anniversary of an ambitious global childhood vaccination program. The Expanded Programme on ...